PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older

Plain-language summary

This study examines the effectiveness of the PCV13 vaccine against hospitalized vaccine-type pneumococcal community-acquired pneumonia in adults aged 60 and older, by collecting urine and saliva samples. It enrolled patients aged 60 and older with evidence of pneumonia within the first 48 hours of hospital admission. The study was conducted as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Pfizer

Intervention

Urine sample collection, Saliva collection

Start date

3/12/2021

Estimated completion

3/24/2024

Countries

Spain

Related genes

Locations

• Getafe, Spain
• Leganés, Spain
• Alcorcón, Spain
• Móstoles, Spain
• Móstoles, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Age ≥60 years.
2. Evidence of pneumonia within first 48 hours of hospital admission
3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

1. Any patient who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at current hospital, another transferring hospital, or a combination of these).
2. Previously enrolled subjects readmitted ≤14 days after discharge for their study qualifying admission.
3. At the time of enrollment, pneumonia has been excluded as the diagnosis or another diagnosis confirmed.